Elicio Therapeutics Secures a Total of $73 Million in Series B Financing

– Elicio Therapeutics secured a total of $73m in Series B financing.
– The funding was established from an international investor base, including multiple strategic and institutional investors.
– Proceeds will advance Elicio’s lead program ELI-002 into clinical trials in early 2021 for mutated KRAS (mKRAS) driven cancers, estimated to be 25% of all human solid tumors.
– ELI-002 contains two powerful components: The company’s proprietary immune stimulating Amphiphile (AMP)-CpG, an adjuvant, and AMP mKRAS peptides which target a broad spectrum of KRAS mutations that drive 97% of all KRAS-driven cancers.